Antidepressants and Mood Stabilizers: PhLE (Licensure Exam) Pharmacology and Pharmacokinetics Mastery

Introduction to Antidepressants and Mood Stabilizers for the PhLE

As an aspiring pharmacist in the Philippines, your comprehensive understanding of psychopharmacology, particularly antidepressants and mood stabilizers, is paramount for success in the PhLE (Licensure Exam) Pharmacology and Pharmacokinetics exam. These drug classes represent cornerstones in the management of prevalent mental health conditions such as major depressive disorder, anxiety disorders, and bipolar disorder. The exam will test not only your recall of drug names but also your in-depth knowledge of their mechanisms of action (MOA), pharmacokinetic profiles, adverse effect management, and crucial drug interactions.

The landscape of mental health treatment is dynamic, and pharmacists play a critical role in optimizing patient outcomes through medication management, counseling, and monitoring. A strong grasp of these medications ensures you can competently advise patients, collaborate with prescribers, and identify potential drug-related problems, thereby safeguarding patient well-being. This mini-article will equip you with the focused knowledge necessary to excel in this high-yield area of the PhLE.

Key Concepts: Mechanisms, Pharmacokinetics, and Clinical Pearls

Understanding the core principles of antidepressants and mood stabilizers is vital. We'll delve into the major classes, highlighting their unique characteristics.

Antidepressants

Antidepressants primarily aim to restore the balance of neurotransmitters in the brain, notably serotonin, norepinephrine, and dopamine, which are implicated in mood regulation.

• Selective Serotonin Reuptake Inhibitors (SSRIs)
  • MOA: Selectively block the reuptake of serotonin (5-HT) into the presynaptic neuron, increasing its concentration in the synaptic cleft.
  • Key Drugs: Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram, Fluvoxamine.
  • Pharmacokinetics: Generally well-absorbed orally. Most undergo hepatic metabolism via CYP450 enzymes, leading to potential drug interactions (e.g., fluoxetine and paroxetine are strong CYP2D6 inhibitors). Half-lives vary; fluoxetine has a very long half-life (days for parent drug and active metabolite).
  • Adverse Effects: Nausea, diarrhea, insomnia/sedation, sexual dysfunction (common), headache. Risk of serotonin syndrome, especially with other serotonergic agents. Discontinuation syndrome upon abrupt cessation.
  • Clinical Pearls: First-line for depression and anxiety. Therapeutic effects may take 2-4 weeks to manifest.
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • MOA: Block the reuptake of both serotonin and norepinephrine.
  • Key Drugs: Venlafaxine, Desvenlafaxine, Duloxetine.
  • Pharmacokinetics: Similar to SSRIs, hepatic metabolism. Venlafaxine is metabolized to desvenlafaxine. Duloxetine is a moderate CYP2D6 inhibitor.
  • Adverse Effects: Similar to SSRIs, but can also cause dose-dependent increases in blood pressure (due to norepinephrine reuptake inhibition), sweating, and urinary retention.
  • Clinical Pearls: Useful for patients with comorbid pain syndromes (duloxetine, venlafaxine).
• Tricyclic Antidepressants (TCAs)
  • MOA: Non-selectively block the reuptake of serotonin and norepinephrine. They also block muscarinic cholinergic, alpha-1 adrenergic, and histamine H1 receptors, contributing to their side effect profile.
  • Key Drugs: Amitriptyline, Imipramine, Nortriptyline, Desipramine.
  • Pharmacokinetics: Highly lipophilic, extensive first-pass metabolism, variable bioavailability. Metabolized by CYP450 enzymes. Narrow therapeutic index; therapeutic drug monitoring (TDM) can be useful.
  • Adverse Effects: Anticholinergic (dry mouth, blurred vision, constipation, urinary retention), orthostatic hypotension (alpha-1 blockade), sedation (H1 blockade), weight gain. Cardiotoxicity (QT prolongation, arrhythmias) and seizures in overdose are significant.
  • Clinical Pearls: Less commonly used first-line due to side effects and toxicity risk, but effective for severe depression, neuropathic pain, and migraine prophylaxis.
• Monoamine Oxidase Inhibitors (MAOIs)
  • MOA: Inhibit the enzyme monoamine oxidase, which metabolizes serotonin, norepinephrine, and dopamine, leading to increased levels of these neurotransmitters.
  • Key Drugs: Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline (transdermal patch avoids gut MAO-A inhibition at lower doses).
  • Pharmacokinetics: Irreversible inhibition of MAO, meaning enzyme activity must be regenerated, leading to prolonged effects even after discontinuation.
  • Adverse Effects: Orthostatic hypotension, weight gain, sexual dysfunction. Major concern: Hypertensive crisis with tyramine-rich foods or sympathomimetics due to inhibition of MAO-A in the gut. Risk of serotonin syndrome with other serotonergic drugs.
  • Clinical Pearls: Reserved for atypical depression or treatment-resistant depression due to significant food and drug interactions.
• Atypical Antidepressants
  • Bupropion: Norepinephrine and dopamine reuptake inhibitor (NDRI). No sexual dysfunction. Risk of seizures at higher doses. Also used for smoking cessation.
  • Mirtazapine: Alpha-2 antagonist, increasing norepinephrine and serotonin release. Also potent H1 antagonist (sedation, weight gain). Good for insomnia/anorexia.
  • Trazodone: Serotonin antagonist and reuptake inhibitor (SARI). Potent alpha-1 and H1 antagonist. Primarily used off-label for insomnia due to significant sedation. Priapism is a rare but serious side effect.
  • Vortioxetine: Multimodal antidepressant. Inhibits serotonin reuptake, acts as a 5-HT3 receptor antagonist, 5-HT1A receptor agonist, and 5-HT1B receptor partial agonist.
  • Vilazodone: SSRI and 5-HT1A receptor partial agonist.

Mood Stabilizers

Mood stabilizers are primarily used to treat bipolar disorder, aiming to reduce the intensity and frequency of both manic and depressive episodes.

• Lithium
  • MOA: Not fully understood, but involves altering ion transport across cell membranes, modulating second messenger systems, and inhibiting enzymes like inositol monophosphatase.
  • Pharmacokinetics: Renally excreted. No hepatic metabolism. Has a narrow therapeutic index, necessitating therapeutic drug monitoring (TDM). Target serum levels: 0.6-1.2 mEq/L (acute mania), 0.6-1.0 mEq/L (maintenance).
  • Adverse Effects:
    • Common: Tremor, polyuria/polydipsia (nephrogenic diabetes insipidus), nausea, diarrhea, weight gain.
    • Toxic (levels > 1.5 mEq/L): Ataxia, confusion, coarse tremor, seizures, arrhythmias, coma.
  • Drug Interactions: NSAIDs, thiazide diuretics, ACE inhibitors can increase lithium levels. Avoid dehydration.
  • Clinical Pearls: First-line for acute mania and maintenance in bipolar disorder. Monitor renal and thyroid function.
• Anticonvulsants as Mood Stabilizers
  • Valproic Acid (Divalproex Sodium)
    • MOA: Increases GABA levels in the brain, modulates voltage-gated sodium channels, and may affect second messenger systems.
    • Pharmacokinetics: Hepatic metabolism (CYP450 inhibitor). Highly protein-bound. TDM target serum levels: 50-125 mcg/mL.
    • Adverse Effects: Nausea, vomiting, sedation, tremor, weight gain, alopecia. Serious: Hepatotoxicity (especially in young children), pancreatitis, thrombocytopenia, neural tube defects in pregnancy.
    • Clinical Pearls: Effective for acute mania and mixed episodes, rapid cycling bipolar disorder.
  • Carbamazepine
    • MOA: Blocks voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting repetitive neuronal firing.
    • Pharmacokinetics: Hepatic metabolism (autoinduction of its own metabolism, strong CYP3A4 inducer). TDM target serum levels: 4-12 mcg/mL.
    • Adverse Effects: Dizziness, drowsiness, ataxia, nausea. Serious: Aplastic anemia, agranulocytosis (monitor CBC), hyponatremia (SIADH), Steven-Johnson Syndrome (especially in patients with HLA-B*1502 allele, common in Asian populations).
    • Clinical Pearls: Effective for acute mania, mixed episodes, and rapid cycling.
  • Lamotrigine
    • MOA: Blocks voltage-gated sodium channels and inhibits glutamate release.
    • Pharmacokinetics: Hepatic metabolism (glucuronidation). Half-life is significantly affected by valproic acid (increases) and carbamazepine (decreases).
    • Adverse Effects: Dizziness, ataxia, blurred vision, nausea. Serious: Skin rash, including Stevens-Johnson Syndrome/TEN (titrate slowly to minimize risk).
    • Clinical Pearls: Primarily for bipolar depression maintenance, less effective for acute mania. Slow titration is crucial.

How It Appears on the PhLE (Licensure Exam) Pharmacology and Pharmacokinetics Exam

The PhLE often presents questions on antidepressants and mood stabilizers in various formats, testing both foundational knowledge and clinical application.

• Direct Recall: "Which of the following is an SSRI?" or "What is the primary mechanism of action of lithium?"
• Scenario-Based Questions: A patient presents with symptoms of depression and is prescribed fluoxetine. What side effect should the pharmacist counsel them about regarding sexual function?
• Drug Interaction Scenarios: A patient on phenelzine is prescribed an over-the-counter decongestant containing pseudoephedrine. What is the potential adverse reaction? Or, a patient on lithium starts taking ibuprofen daily; what is the pharmacokinetic consequence?
• Adverse Effect Identification: A patient on carbamazepine develops a severe rash and fever. What life-threatening condition should be suspected?
• Pharmacokinetic Application: Questions about half-life, metabolism, or the need for TDM for drugs like lithium, valproic acid, or carbamazepine.
• Patient Counseling: How would you advise a patient starting venlafaxine regarding its onset of action and potential side effects?
• Contraindications and Precautions: Identifying specific patient populations or conditions where certain drugs are contraindicated (e.g., pregnancy for valproic acid, cardiac history for TCAs).

Expect questions that require you to differentiate between drug classes, identify hallmark adverse effects, and apply pharmacokinetic principles to clinical situations. For more practice, consider exploring PhLE (Licensure Exam) Pharmacology and Pharmacokinetics practice questions.

Study Tips for Mastering Antidepressants and Mood Stabilizers

Efficient studying is key to covering the breadth of this topic effectively:

1. Categorize by MOA: Grouping drugs by their mechanism helps solidify understanding and differentiate between similar-sounding medications. Create charts comparing SSRIs, SNRIs, TCAs, and MAOIs side-by-side for MOA, side effects, and interactions.
2. Focus on High-Yield Information: Prioritize unique or severe adverse effects (e.g., serotonin syndrome, hypertensive crisis, SJS, cardiotoxicity of TCAs, hepatotoxicity of valproic acid), critical drug interactions, and the necessity of TDM.
3. Mnemonics and Flashcards: Develop memory aids for drug classes, their primary side effects, and key interactions. Flashcards are excellent for quick recall of MOA, indications, and adverse effects.
4. Understand the "Why": Don't just memorize; understand why a drug causes certain side effects (e.g., anticholinergic effects of TCAs are due to muscarinic blockade). This deeper understanding improves retention.
5. Practice with Clinical Scenarios: Work through case studies. Imagine you're the pharmacist counseling a patient or identifying a potential drug interaction. This simulates exam conditions. You can find free practice questions on our site.
6. Review Pharmacokinetics: Pay close attention to absorption, distribution, metabolism (especially CYP450 involvement), and excretion for each major drug. This explains dosing adjustments, interactions, and TDM needs.
7. Create a "Dangerous Interactions" List: Specifically list combinations like MAOIs + SSRIs/SNRIs, lithium + NSAIDs, carbamazepine + HLA-B*1502.

Common Mistakes to Watch Out For

Avoiding these common pitfalls can significantly improve your score:

• Confusing MOAs: Mixing up selective reuptake inhibitors with non-selective ones, or forgetting the additional receptor blockades of TCAs.
• Underestimating Drug Interactions: Failing to recognize critical interactions, especially those leading to severe adverse events (e.g., serotonin syndrome, hypertensive crisis).
• Ignoring Therapeutic Drug Monitoring (TDM) Requirements: Not knowing which drugs require TDM (lithium, valproic acid, carbamazepine) and their target ranges, or factors that can alter levels.
• Overlooking Severe Adverse Effects: Forgetting the black box warnings or life-threatening side effects associated with certain drugs (e.g., SJS with lamotrigine/carbamazepine, cardiotoxicity of TCAs in overdose).
• Misinterpreting Onset of Action: Expecting immediate therapeutic effects from antidepressants, leading to premature discontinuation.
• Abrupt Discontinuation: Not understanding the risks of discontinuation syndrome with SSRIs/SNRIs or rebound effects with mood stabilizers.

Quick Review / Summary

Antidepressants and mood stabilizers are central to managing mental health conditions, and their pharmacology forms a significant portion of the PhLE. Remember to differentiate between drug classes based on their specific mechanisms of action, which directly inform their therapeutic uses and side effect profiles. SSRIs and SNRIs are first-line for depression and anxiety, known for their generally favorable safety profiles but with risks like sexual dysfunction and serotonin syndrome. TCAs and MAOIs, while effective, carry greater risks of severe adverse effects and drug interactions, requiring careful monitoring.

Mood stabilizers like lithium, valproic acid, carbamazepine, and lamotrigine are essential for bipolar disorder. Each has distinct pharmacokinetic properties, adverse effects, and monitoring requirements, especially regarding therapeutic drug monitoring for lithium, valproic acid, and carbamazepine due to their narrow therapeutic indices. Pay close attention to drug-drug and drug-food interactions, as these are frequently tested and have significant clinical implications. By focusing on MOA, pharmacokinetics, common and severe adverse effects, and critical interactions, you'll be well-prepared to tackle these topics on the PhLE.